Author Archives: Bruno Quinney

#Cancer research #Immune response #Tumour biology

Novel therapy could slow tumour growth, results find 

A novel cancer therapy targeting tumour acidity could boost immune response and slow cancer growth, studies show.  Biotechnology company Dyve Biosciences, in collaboration with Moffitt Cancer Center, reported results for a first-of-its-kind investigational therapy applied to the skin, which is designed to work throughout the body to target the tumour microenvironment –… Read More

#Cancer Research #News

Clinical trial
#Clinical trials #NHS #UK government

Regulatory reforms accelerate UK clinical trial set up

NHS patients are accessing groundbreaking treatments faster as the UK government fulfils its promise for a 150-day clinical trial target.  The latest UK Clinical Research Delivery key performance indicators show the average time to set up a commercial interventional clinical trial has fallen from 169 days to 122 days when comparing the same six month period this year to last.  The improvement follows… Read More

#News #Regulatory

CANTAB
#Clinical research #SynaptixBio

Speech overlooked as clinical marker, biotech says 

Speech is an ‘underestimated’ clinical marker in neurodegenerative disease research, SynaptixBio has said.  The biotech, which became the only company to commercialise a treatment for the rare disease H-ABC, is set to launch a study into speech as a non-invasive, digital clinical marker in neurodegenerative disease research.  … Read More

#News

#Infectious diseases #Pandemic prevention #University of Texas

Research collaboration to ‘strengthen pandemic preparedness’ 

Life science company ProImmune has announced a collaboration with The University of Texas Medical Branch (UTMB) to partner on research into infectious diseases.  The collaboration will combine ProImmune’s Ankyron target binding reagent technology with expertise at the Galveston National Laboratory (GNL), part of UTMB, in the immunopathology of emerging viruses.   Under the… Read More

#News

#Life sciences #UK

Construction completed on new UK life science facility 

Construction of a 56,000 sq ft UK life science facility has been completed, Aviva Investors has announced.  Chesterford Research Park, owned by Aviva Investors, now includes ten fully-fitted research and development suites spread over three floors, bringing capacity to approximately 385,000 sq ft of net internal space to UK life science… Read More

#News

Drug manufacturing
#AstraZeneca #England #Hyperkalaemia #Wales

Access to hyperkalaemia drug expands across England and Wales 

Access to AstraZeneca’s hyperkalaemia treatment Lokelma has been expanded across England and Wales.  AstraZeneca announced the National Institute for Health and Care Excellence (NICE) had issued a draft recommendation for lokelma (sodium zirconium cyclosilicate). Under the new willingness-to-pay threshold, more than double the number of patients could be eligible for… Read More

#News #Regulatory

Arthritis
#Arthritis #University of Birmingham

Immunopeptide could delay inflammatory arthritis, study says 

An immunopeptide could help prevent or delay early-stage inflammatory arthritis, research shows.  Scientists investigating the naturally occurring immunopeptide PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) have shown reductions in arthritic joint swelling to a degree comparable to the current standard of care, reducing inflammatory changes that cause joint damage. … Read More

#News

#Autoimmune disease #Biotechnology #Inflammatory diseases

Laigo Bio announces new CSO as part of board appointments 

Biotechnology company Laigo Bio has appointed Dr Richard Sainson as Chief Scientific Officer as part of a swathe of board appointments.  The company, which specialises in autoimmune and inflammatory diseases, says Sainson will lead scientific strategy and oversee the advancement of Laigo’s proprietary SureTACs platform and programmes towards the clinic.   Sainson has over 25… Read More

#News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#Cancer research #Investment

Incyclix Bio raises extra $5m to advance cancer treatment 

Incyclix Bio has raised an additional $5 million in Series B financing to support its treatment for advanced and resistant cancers.  The cell cycle control company raised the funds from new investor Hatteras Venture Partners, which will help advance Incyclix Bio’s lead compound INX-315. The compound is a novel, potent and selective CDK2 inhibitor… Read More

#Business & Investment #News

Treg cells
#Kainova Therapeutics #Monotherapy #Tregs

Kainova Therapeutics doses first patient with cancer monotherapy 

Kainova Therapeutics has dosed the first patient with its Treg-depleting monotherapy.  The biopharmaceutical company dosed the patient in a Phase I/II clinical trial of DT-7012, a proprietary Treg depleting antiCCR8 monoclonal antibody, in patients with advanced solid tumours.  The study is evaluating DT7012 as monotherapy… Read More

#News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

#Canada #Fujifilm #Japan

Collaboration to advance AAV production enhancers 

A Canadian Japanese co-innovation programme is set to advance AAV production enhancers.  AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they remain difficult and expensive to manufacture at scale. As pipelines expand to more indications and broader patient populations, significantly greater amounts of… Read More

#News

#AI #Chemify #Drug discovery

Chemify’s drug discovery platform validated by papers

A platform helping drug discovery companies take a novel concept to makeable compound has been validated in three academic papers.  Chemify says its Chemputation platform, which integrates AI- and ML-driven molecular discovery and automated robotic synthesis, has been validated as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. … Read More

#News

#Concussion #Investment #Oxeia Biopharmaceuticals

Oxeia surpasses funding goal for concussion therapy 

Biotech company Oxeia Biopharmaceuticals has announced its first crowdfunding campaign was oversubscribed, raising over $1.2 million before its scheduled close.  The company, which develops concussion therapeutics, has surpassed its crowdfunding goal, reflecting interest in its clinical-stage ghrelin therapy for persistent concussion symptoms.  The therapy, OXE103, demonstrated an 85% responder rate compared to 33%… Read More

#Business & Investment #News

MRI showing glioblastoma
#Brain cancer #Gene therapy #Trogenix

Gene therapy could eradicate tumours in brain cancer 

An innovative gene therapy could achieve complete tumour elimination in brain cancer, data shows.  Biotechnology company Trogenix has announced the publication of breakthrough preclinical data, reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM).  The results, published in … Read More

#Cancer Research #News